Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-29T03:18:32.405Z Has data issue: false hasContentIssue false
  • English
  • Français

Parkinson's Disease Management: Towards a New Paradigm

Published online by Cambridge University Press:  02 December 2014

Mark Guttman  and
Oksana Suchowersky
Mark Guttman
Affiliation:
The Division of Neurology, Department of Medicine, Department of Psychiatry, University of Toronto, Toronto, Ontario
Oksana Suchowersky
Affiliation:
The Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Over the past decade, management of Parkinson's disease has changed significantly due to the expansion of medical and surgical treatment modalities. Neurologists now have the ability (and the challenge) of choosing from multiple medications to devise an individual management strategy for each patient depending on his/her clinical symptoms and needs. Several different surgical therapies are also available. The topics covered in this supplement have highlighted the new options that are now available, as well as the treatments that have been in clinical usage. This review attempts to synthesize the information that is currently available in an attempt to help clinical neurologists make the appropriate choice for their patients.

Résumé

RÉSUMÉ

Dans la dernière décennie, le traitement de la maladie de Parkinson a changé beaucoup à cause des nouveaux modes de traitements médicaux et chirurgicaux. Les neurologues ont maintenant la capacité (et le défi) de choisir parmi de nombreux médicaments pour définir une stratégie de traitement individualisée pour chaque patient selon ses symptômes cliniques et ses besoins. Plusieurs traitements chirurgicaux sont également disponibles. Les sujets couverts dans ce supplément ont illustré les nouvelles options maintenant disponibles ainsi que les traitements d'usage courant dans le but d'aider les neurologues à faire des choix appropriés pour leurs patients en clinique.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 26 , Issue S2 , August 1999 , pp. S53 - S57
Copyright
Copyright © The Canadian Journal of Neurological 1999

References

1. Blanchet, PJ. Rationale for use of dopamine agonists in Parkinson’s disease: review of ergot derivatives. Can J Neurol Sci 1999; (this issue).Google Scholar
2. Grimes, DA, Lang, AE. Treatment of early Parkinson’s disease. Can J Neurol Sci 1999; (this issue).Google Scholar
3. Verhagen Metman, VL, Del Dotto, P, van der Munckhof, P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in PD. Neurology 1998; 50: 1323–1326.Google Scholar
4. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Ann Neurol 1998; 39: 29–36.Google Scholar
5. Rivest, J, Barclay, CL, Suchowersky, O. COMT inhibitors in Parkinson’s disease. Can J Neurol Sci 1999; (this issue).Google Scholar
6. Hobson, DE, Pourcher, E, Martin, WRW. Ropinirole and pramipex-ole, the new agonists. Can J Neurol Sci 1999; (this issue).Google Scholar
7. Honey, C, Gross, RE, Lozano, AM. New developments in the surgery for Parkinson’s disease. Can J Neurol Sci 1999; (this issue).Google Scholar
8. Greenmayre, JT, Eller, RV, Zhang, Z, et al. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist in rodent and primate models. Ann Neurol 1994; 35: 655–661.Google Scholar
9. Steiner, JP, Hamilton, GS, Ross, DT, et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Nat Acad Sci 1997; 3: 421–428.Google Scholar
10. Dewey, RB, Maraganore, DM, Ahlskog, JE, Matsumoto, JY. A double blind, placebo controlled study of intranasal apomorphine spray as rescue agent for off-states in Parkinson’s disease. Mov Disord 1998; 13: 782–787.CrossRefGoogle ScholarPubMed
11. Calabrese, VP, Lloyd, KA, Broncazio, P, et al. N-0923, a novel soluble dopamine D2 agonist in the treatment of Parkinsonism. Mov Disord 1998; 13: 768–774.CrossRefGoogle ScholarPubMed
12. Gash, DM, Zhang, Z, Ovadia, A, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996; 380(6571): 252–255.CrossRefGoogle ScholarPubMed
13. Kanda, T, Jackson, MJ, Smith, LA, et al. Adenosine A2a antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998; 43: 507–513.Google Scholar
14. Guttman M for the International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocrip-tine treatment with placebo in advanced Parkinson’s disease. Neurology 1997; 49: 1060–1065.Google Scholar